Loading stock data…
$12.06-0.23 (-1.87%)
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Trevi Therapeutics, Inc. in the Healthcare sector is trading at $12.06 with a market capitalization of $2.4B. Wall Street consensus targets $28.18 (11 analysts), implying a +133.7% move over the next 12 months. The stock is currently 40% below its 52-week high of $20.22, remaining 15.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$20.51M↓ | -$14.91M↓ | -$10.22M↑ | -$13.92M↓ | -$13.72M |
| Net Income | -$17.80M↓ | -$13.19M↓ | -$8.32M↑ | -$11.80M↑ | -$12.30M |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, a...